3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
3
Lymphoma, T-Cell, Cutaneous
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Interventions
aldesleukin
15
pembrolizumab
11
Cyclophosphamide
9
fludarabine phosphate
7
fludarabine
6
Nivolumab
6
Interleukin-2
6
atezolizumab
5
Radiotherapy
5
Ipilimumab
4
Interferon-alpha
4
Drug Therapy
4
Blood Specimen Collection
4
Radiosurgery
3
tremelimumab
2
temsirolimus
2
durvalumab
2
cemiplimab
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Metformin
2
Interleukin-12 Subunit p35
2
Genistein
2
Gene Expression Profiling
2
Flow Cytometry
2
Filgrastim
2
Cetuximab
2
zanolimumab
1
vivitrol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Interleukin-15
×
Dermatologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled